Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab

Jürgen Braun, Désirée Van Der Heijde, Mittie K. Doyle, Chenglong Han, Atulya (Atul) Deodhar, Robert Inman, Kurt De Vlam, Gerd R. Burmester, Filip Van Den Bosch, Stephen Xu, Sudha Visvanathan, Mahboob U. Rahman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective. Anemia is a common complication in patients with inflammatory diseases such as ankylosing spondylitis (AS). This post hoc analysis of a large, randomized, placebo-controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS. Methods. Patients received infliximab 5 mg/kg (n = 188) or placebo (n = 68) at weeks 0, 2, 6, 12, and 18. Hemoglobin, interleukin-6 (IL-6), and C-reactive protein (CRP) levels, fatigue (visual analog scale [VAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]), and disease activity were evaluated at baseline and week 24. Anemia was defined as a hemoglobin level

Original languageEnglish (US)
Pages (from-to)1032-1036
Number of pages5
JournalArthritis Care and Research
Volume61
Issue number8
DOIs
StatePublished - Aug 15 2009

Fingerprint

Ankylosing Spondylitis
Hemoglobins
Fatigue
Anemia
Placebos
Visual Analog Scale
Baths
C-Reactive Protein
Interleukin-6
Randomized Controlled Trials
Infliximab

ASJC Scopus subject areas

  • Rheumatology

Cite this

Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. / Braun, Jürgen; Van Der Heijde, Désirée; Doyle, Mittie K.; Han, Chenglong; Deodhar, Atulya (Atul); Inman, Robert; De Vlam, Kurt; Burmester, Gerd R.; Van Den Bosch, Filip; Xu, Stephen; Visvanathan, Sudha; Rahman, Mahboob U.

In: Arthritis Care and Research, Vol. 61, No. 8, 15.08.2009, p. 1032-1036.

Research output: Contribution to journalArticle

Braun, J, Van Der Heijde, D, Doyle, MK, Han, C, Deodhar, AA, Inman, R, De Vlam, K, Burmester, GR, Van Den Bosch, F, Xu, S, Visvanathan, S & Rahman, MU 2009, 'Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab', Arthritis Care and Research, vol. 61, no. 8, pp. 1032-1036. https://doi.org/10.1002/art.24865
Braun, Jürgen ; Van Der Heijde, Désirée ; Doyle, Mittie K. ; Han, Chenglong ; Deodhar, Atulya (Atul) ; Inman, Robert ; De Vlam, Kurt ; Burmester, Gerd R. ; Van Den Bosch, Filip ; Xu, Stephen ; Visvanathan, Sudha ; Rahman, Mahboob U. / Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. In: Arthritis Care and Research. 2009 ; Vol. 61, No. 8. pp. 1032-1036.
@article{3eda3539f91148b5b9fb360cd79e9cc8,
title = "Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab",
abstract = "Objective. Anemia is a common complication in patients with inflammatory diseases such as ankylosing spondylitis (AS). This post hoc analysis of a large, randomized, placebo-controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS. Methods. Patients received infliximab 5 mg/kg (n = 188) or placebo (n = 68) at weeks 0, 2, 6, 12, and 18. Hemoglobin, interleukin-6 (IL-6), and C-reactive protein (CRP) levels, fatigue (visual analog scale [VAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]), and disease activity were evaluated at baseline and week 24. Anemia was defined as a hemoglobin level",
author = "J{\"u}rgen Braun and {Van Der Heijde}, D{\'e}sir{\'e}e and Doyle, {Mittie K.} and Chenglong Han and Deodhar, {Atulya (Atul)} and Robert Inman and {De Vlam}, Kurt and Burmester, {Gerd R.} and {Van Den Bosch}, Filip and Stephen Xu and Sudha Visvanathan and Rahman, {Mahboob U.}",
year = "2009",
month = "8",
day = "15",
doi = "10.1002/art.24865",
language = "English (US)",
volume = "61",
pages = "1032--1036",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab

AU - Braun, Jürgen

AU - Van Der Heijde, Désirée

AU - Doyle, Mittie K.

AU - Han, Chenglong

AU - Deodhar, Atulya (Atul)

AU - Inman, Robert

AU - De Vlam, Kurt

AU - Burmester, Gerd R.

AU - Van Den Bosch, Filip

AU - Xu, Stephen

AU - Visvanathan, Sudha

AU - Rahman, Mahboob U.

PY - 2009/8/15

Y1 - 2009/8/15

N2 - Objective. Anemia is a common complication in patients with inflammatory diseases such as ankylosing spondylitis (AS). This post hoc analysis of a large, randomized, placebo-controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS. Methods. Patients received infliximab 5 mg/kg (n = 188) or placebo (n = 68) at weeks 0, 2, 6, 12, and 18. Hemoglobin, interleukin-6 (IL-6), and C-reactive protein (CRP) levels, fatigue (visual analog scale [VAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]), and disease activity were evaluated at baseline and week 24. Anemia was defined as a hemoglobin level

AB - Objective. Anemia is a common complication in patients with inflammatory diseases such as ankylosing spondylitis (AS). This post hoc analysis of a large, randomized, placebo-controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS. Methods. Patients received infliximab 5 mg/kg (n = 188) or placebo (n = 68) at weeks 0, 2, 6, 12, and 18. Hemoglobin, interleukin-6 (IL-6), and C-reactive protein (CRP) levels, fatigue (visual analog scale [VAS]), physical function (Bath Ankylosing Spondylitis Functional Index [BASFI]), and disease activity were evaluated at baseline and week 24. Anemia was defined as a hemoglobin level

UR - http://www.scopus.com/inward/record.url?scp=68149172593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149172593&partnerID=8YFLogxK

U2 - 10.1002/art.24865

DO - 10.1002/art.24865

M3 - Article

VL - 61

SP - 1032

EP - 1036

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -